This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Ibogaine
Long-acting iboga alkaloid with real published signal for interrupting opioid withdrawal and reducing relapse — used in foreign-clinic OUD treatment industry.
Aliases (5)
Overview
What is Ibogaine?
Long-acting iboga alkaloid with real published signal for interrupting opioid withdrawal and reducing relapse — used in foreign-clinic OUD treatment industry. Also the most cardiotoxic psychedelic, with ~1/300-400 field-clinic fatality rate from QTc prolongation. SKIP-PERMANENT outside a full medical/cardiology-cleared OUD context.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Acute experience: ~24-36h waking-dream / "movie-like" autobiographical visions; ataxia; nausea; bradycardia; deep introspective phase.
- Cardiac: QTc prolongation peaks 6-24h post-dose; torsades risk window extends to 72h. Magnesium loading reduces but does not eliminate.
- Post-acute: afterglow + insomnia 2-7 days; protracted re-integration.
- Cerebellar: rare ataxia at supratherapeutic dose; reversibility uncertain.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.